-
1
-
-
84861569538
-
Antiphosphatidylserine/prothrombin antibodies in primary antiphospholipid syndrome
-
COI: 1:CAS:528:DC%2BC38XhtFWhtbzI, PID: 22635234
-
Hoxha A, Ruffatti A, Tonello M, Bontadi A, Salvan E, Banzato A, et al. Antiphosphatidylserine/prothrombin antibodies in primary antiphospholipid syndrome. Lupus. 2012;21:787–9.
-
(2012)
Lupus
, vol.21
, pp. 787-789
-
-
Hoxha, A.1
Ruffatti, A.2
Tonello, M.3
Bontadi, A.4
Salvan, E.5
Banzato, A.6
-
3
-
-
84908518375
-
The coexistence of antiphospholipid syndrome and systemic lupus erythematosus in Colombians
-
PID: 25343509
-
Franco J-S, Molano-González N, Rodríguez-Jiménez M, Acosta-Ampudia Y, Mantilla RD, Amaya-Amaya J, et al. The coexistence of antiphospholipid syndrome and systemic lupus erythematosus in Colombians. PLoS ONE. 2014;9:e110242.
-
(2014)
PLoS ONE
, vol.9
, pp. e110242
-
-
Franco, J.-S.1
Molano-González, N.2
Rodríguez-Jiménez, M.3
Acosta-Ampudia, Y.4
Mantilla, R.D.5
Amaya-Amaya, J.6
-
4
-
-
33845600231
-
The prevalence of antiphospholipid antibody syndrome among systemic lupus erythematosus patients
-
COI: 1:STN:280:DC%2BD2s%2Fns1eitw%3D%3D, PID: 17274170
-
McMahon MA, Keogan M, O'Connell P, Kearns G. The prevalence of antiphospholipid antibody syndrome among systemic lupus erythematosus patients. Ir Med J. 2006;99:296–8.
-
(2006)
Ir Med J
, vol.99
, pp. 296-298
-
-
McMahon, M.A.1
Keogan, M.2
O'Connell, P.3
Kearns, G.4
-
5
-
-
22644441144
-
Long-term follow-up in 128 patients with primary antiphospholipid syndrome: do they develop lupus?
-
Gómez-Puerta JA, Martín H, Amigo M-C, Aguirre MA, Camps MT, Cuadrado MJ, et al. Long-term follow-up in 128 patients with primary antiphospholipid syndrome: do they develop lupus? Medicine (Baltimore). 2005;84:225–30.
-
(2005)
Medicine (Baltimore)
, vol.84
, pp. 225-230
-
-
Gómez-Puerta, J.A.1
Martín, H.2
Amigo, M.-C.3
Aguirre, M.A.4
Camps, M.T.5
Cuadrado, M.J.6
-
6
-
-
33344458573
-
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)
-
Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost. 2006;6:295–306.
-
(2006)
J. Thromb. Haemost
, vol.6
, pp. 295-306
-
-
Miyakis, S.1
Lockshin, M.D.2
Atsumi, T.3
Branch, D.W.4
Brey, R.L.5
Cervera, R.6
-
7
-
-
84896537523
-
Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: a systematic review and meta-analysis
-
COI: 1:CAS:528:DC%2BC2cXhsVyju70%3D, PID: 24418303
-
Reynaud Q, Lega J-C, Mismetti P, Chapelle C, Wahl D, Cathébras P, et al. Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: a systematic review and meta-analysis. Autoimmun Rev. 2014;13:595–608.
-
(2014)
Autoimmun Rev
, vol.13
, pp. 595-608
-
-
Reynaud, Q.1
Lega, J.-C.2
Mismetti, P.3
Chapelle, C.4
Wahl, D.5
Cathébras, P.6
-
8
-
-
0034631861
-
Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: do the benefits outweigh the risks? A decision analysis
-
COI: 1:STN:280:DC%2BD3czkslKmsg%3D%3D, PID: 10888978
-
Wahl DG, Bounameaux H, de Moerloose P, Sarasin FP. Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: do the benefits outweigh the risks? A decision analysis. Arch Intern Med. 2000;160:2042–8.
-
(2000)
Arch Intern Med
, vol.160
, pp. 2042-2048
-
-
Wahl, D.G.1
Bounameaux, H.2
de Moerloose, P.3
Sarasin, F.P.4
-
9
-
-
0037370733
-
Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature
-
COI: 1:CAS:528:DC%2BD3sXhslCrtrk%3D, PID: 12393574
-
Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood. 2003;101:1827–32.
-
(2003)
Blood
, vol.101
, pp. 1827-1832
-
-
Galli, M.1
Luciani, D.2
Bertolini, G.3
Barbui, T.4
-
10
-
-
20444446334
-
Antibody profiles for the diagnosis of antiphospholipid syndrome
-
COI: 1:CAS:528:DC%2BD2MXls1Wju74%3D, PID: 15968401
-
Pengo V, Biasiolo A, Pegoraro C, Cucchini U, Noventa F, Iliceto S. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost. 2005;93:1147–52.
-
(2005)
Thromb Haemost
, vol.93
, pp. 1147-1152
-
-
Pengo, V.1
Biasiolo, A.2
Pegoraro, C.3
Cucchini, U.4
Noventa, F.5
Iliceto, S.6
-
11
-
-
0026659095
-
Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients
-
COI: 1:STN:280:DyaK38zksVWmtQ%3D%3D, PID: 1637025
-
Rosove MH, Brewer PM. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med. 1992;117:303–8.
-
(1992)
Ann Intern Med
, vol.117
, pp. 303-308
-
-
Rosove, M.H.1
Brewer, P.M.2
-
12
-
-
84893175081
-
Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review
-
COI: 1:CAS:528:DC%2BC2cXivFejsLw%3D, PID: 24172938
-
Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML. Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review. Thromb Haemost. 2014;111:354–64.
-
(2014)
Thromb Haemost
, vol.111
, pp. 354-364
-
-
Sciascia, S.1
Sanna, G.2
Murru, V.3
Roccatello, D.4
Khamashta, M.A.5
Bertolaccini, M.L.6
-
13
-
-
84856371421
-
Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events
-
COI: 1:CAS:528:DC%2BC38Xht1yrurg%3D, PID: 21953404
-
Otomo K, Atsumi T, Amengual O, Fujieda Y, Kato M, Oku K, et al. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum. 2012;64:504–12.
-
(2012)
Arthritis Rheum
, vol.64
, pp. 504-512
-
-
Otomo, K.1
Atsumi, T.2
Amengual, O.3
Fujieda, Y.4
Kato, M.5
Oku, K.6
-
14
-
-
67149087369
-
Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus
-
COI: 1:CAS:528:DC%2BD1MXotlSjt7k%3D, PID: 19447935
-
Danowski A, de Azevedo MNL, de Souza Papi JA, Petri M. Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus. J Rheumatol. 2009;36:1195–9.
-
(2009)
J Rheumatol
, vol.36
, pp. 1195-1199
-
-
Danowski, A.1
de Azevedo, M.N.L.2
de Souza Papi, J.A.3
Petri, M.4
-
15
-
-
84892372616
-
Risk factors for arterial thrombosis in antiphospholipid syndrome
-
COI: 1:CAS:528:DC%2BC3sXhvFOgtrnP, PID: 24321419
-
Matyja-Bednarczyk A, Swadźba J, Iwaniec T, Sanak M, Dziedzina S, Ćmiel A, et al. Risk factors for arterial thrombosis in antiphospholipid syndrome. Thromb Res. 2014;133:173–6.
-
(2014)
Thromb Res
, vol.133
, pp. 173-176
-
-
Matyja-Bednarczyk, A.1
Swadźba, J.2
Iwaniec, T.3
Sanak, M.4
Dziedzina, S.5
Ćmiel, A.6
-
16
-
-
61449186513
-
Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study
-
COI: 1:STN:280:DC%2BD1M7jslWmsA%3D%3D, PID: 18812393
-
Ruffatti A, Del Ross T, Ciprian M, Nuzzo M, Rampudda M, Bertero MT, et al. Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study. Ann Rheum Dis. 2009;68:397–9.
-
(2009)
Ann Rheum Dis
, vol.68
, pp. 397-399
-
-
Ruffatti, A.1
Del Ross, T.2
Ciprian, M.3
Nuzzo, M.4
Rampudda, M.5
Bertero, M.T.6
-
17
-
-
79955815184
-
Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study
-
PID: 21285115
-
Ruffatti A, Del Ross T, Ciprian M, Bertero MT, Sciascia S, Salvatore S, et al. Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. Ann Rheum Dis. 2011;70:1083–6.
-
(2011)
Ann Rheum Dis
, vol.70
, pp. 1083-1086
-
-
Ruffatti, A.1
Del Ross, T.2
Ciprian, M.3
Bertero, M.T.4
Sciascia, S.5
Salvatore, S.6
-
18
-
-
70449729881
-
Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study
-
COI: 1:CAS:528:DC%2BD1MXhsVertbbL, PID: 19783216
-
Urbanus RT, Siegerink B, Roest M, Rosendaal FR, de Groot PG, Algra A. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol. 2009;8:998–1005.
-
(2009)
Lancet Neurol
, vol.8
, pp. 998-1005
-
-
Urbanus, R.T.1
Siegerink, B.2
Roest, M.3
Rosendaal, F.R.4
de Groot, P.G.5
Algra, A.6
-
19
-
-
3442901073
-
Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals
-
PID: 15290736
-
Girón-González JA, García del Río E, Rodríguez C, Rodríguez-Martorell J, Serrano A. Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals. J Rheumatol. 2004;31:1560–7.
-
(2004)
J Rheumatol
, vol.31
, pp. 1560-1567
-
-
Girón-González, J.A.1
García del Río, E.2
Rodríguez, C.3
Rodríguez-Martorell, J.4
Serrano, A.5
-
20
-
-
79955543065
-
Obesity in primary antiphospholipid syndrome is associated with worse outcome
-
PID: 21196129
-
Caldas CA, da Mota LMH, de Carvalho JF. Obesity in primary antiphospholipid syndrome is associated with worse outcome. Joint Bone Spine. 2011;78:324–5.
-
(2011)
Joint Bone Spine
, vol.78
, pp. 324-325
-
-
Caldas, C.A.1
da Mota, L.M.H.2
de Carvalho, J.F.3
-
21
-
-
84962542199
-
Patients with antiphosholipid syndrome and thrombotic recurrences: a real world observation (the Piedmont cohort study)
-
COI: 1:CAS:528:DC%2BC2MXptlKltLg%3D
-
Bazzan M, Vaccarino A, Stella S, Sciascia S, Montaruli B, Bertero MT, et al. Patients with antiphosholipid syndrome and thrombotic recurrences: a real world observation (the Piedmont cohort study). Lupus. 2015;0:1–7.
-
(2015)
Lupus
, pp. 1-7
-
-
Bazzan, M.1
Vaccarino, A.2
Stella, S.3
Sciascia, S.4
Montaruli, B.5
Bertero, M.T.6
-
22
-
-
84943159990
-
Diabetes increases the risk of deep-vein thrombosis and pulmonary embolism. A population-based cohort study
-
PID: 26271946
-
Chung W-S, Lin C-L, Kao C-H. Diabetes increases the risk of deep-vein thrombosis and pulmonary embolism. A population-based cohort study. Thromb Haemost. 2015;114:812–8.
-
(2015)
Thromb Haemost
, vol.114
, pp. 812-818
-
-
Chung, W.-S.1
Lin, C.-L.2
Kao, C.-H.3
-
23
-
-
0037341535
-
Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use
-
COI: 1:CAS:528:DC%2BD3sXitlSktLk%3D, PID: 12624633
-
Abdollahi M, Cushman M, Rosendaal FR. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb Haemost. 2003;89:493–8.
-
(2003)
Thromb Haemost
, vol.89
, pp. 493-498
-
-
Abdollahi, M.1
Cushman, M.2
Rosendaal, F.R.3
-
24
-
-
34848828529
-
Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations
-
PID: 17897305
-
Pomp ER, le Cessie S, Rosendaal FR, Doggen CJM. Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations. Br J Haematol. 2007;139:289–96.
-
(2007)
Br J Haematol
, vol.139
, pp. 289-296
-
-
Pomp, E.R.1
le Cessie, S.2
Rosendaal, F.R.3
Doggen, C.J.M.4
-
25
-
-
84928739450
-
The global anti-phospholipid syndrome score in primary APS
-
This article validates the use of GAPSS in a cohort of primary APS patients
-
Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML. The global anti-phospholipid syndrome score in primary APS. Rheumatology (Oxford). 2015;54:134–8. This article validates the use of GAPSS in a cohort of primary APS patients.
-
(2015)
Rheumatology (Oxford)
, vol.54
, pp. 134-138
-
-
Sciascia, S.1
Sanna, G.2
Murru, V.3
Roccatello, D.4
Khamashta, M.A.5
Bertolaccini, M.L.6
-
26
-
-
45149103015
-
Double heterozygosity polymorphisms for platelet glycoproteins Ia/IIa and IIb/IIIa increases arterial thrombosis and arteriosclerosis in patients with the antiphospholipid syndrome or with systemic lupus erythematosus
-
PID: 17728329
-
Jiménez S, Tàssies D, Espinosa G, García-Criado A, Plaza J, Monteagudo J, et al. Double heterozygosity polymorphisms for platelet glycoproteins Ia/IIa and IIb/IIIa increases arterial thrombosis and arteriosclerosis in patients with the antiphospholipid syndrome or with systemic lupus erythematosus. Ann Rheum Dis. 2008;67:835–40.
-
(2008)
Ann Rheum Dis
, vol.67
, pp. 835-840
-
-
Jiménez, S.1
Tàssies, D.2
Espinosa, G.3
García-Criado, A.4
Plaza, J.5
Monteagudo, J.6
-
27
-
-
84892468824
-
Can inherited thrombophilia modulate the clinical phenotype of patients with antiphospholipid syndrome?
-
PID: 24093662
-
Berman H, Ugarte-Gil MF, Espinosa G, Tàssies D, Monteagudo J, Reverter JC, et al. Can inherited thrombophilia modulate the clinical phenotype of patients with antiphospholipid syndrome? Clin Exp Rheumatol. 2013;31:926–32.
-
(2013)
Clin Exp Rheumatol
, vol.31
, pp. 926-932
-
-
Berman, H.1
Ugarte-Gil, M.F.2
Espinosa, G.3
Tàssies, D.4
Monteagudo, J.5
Reverter, J.C.6
-
28
-
-
84858283382
-
Mackie I, Moore GW, Greer IA, Greaves M, British Committee for Standards in Haematology. Guidelines on the investigation and management of antiphospholipid syndrome
-
Keeling D, Mackie I, Moore GW, Greer IA, Greaves M, British Committee for Standards in Haematology. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol. 2012;157:47–58.
-
(2012)
Br J Haematol
, vol.157
, pp. 47-58
-
-
-
30
-
-
27644592520
-
Antiphospholipid antibodies in young adults with stroke
-
COI: 1:CAS:528:DC%2BD2MXhtVKqu7fK, PID: 16205859
-
Brey RL. Antiphospholipid antibodies in young adults with stroke. J Thromb Thrombolysis. 2005;20:105–12.
-
(2005)
J Thromb Thrombolysis
, vol.20
, pp. 105-112
-
-
Brey, R.L.1
-
31
-
-
0031919292
-
Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group
-
COI: 1:STN:280:DyaK1c3jsF2guw%3D%3D, PID: 9576405
-
Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. Am J Med. 1998;104:332–8.
-
(1998)
Am J Med
, vol.104
, pp. 332-338
-
-
Schulman, S.1
Svenungsson, E.2
Granqvist, S.3
-
32
-
-
0033602514
-
A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism
-
COI: 1:CAS:528:DyaK1MXit1aitb0%3D, PID: 10089183
-
Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med. 1999;340:901–7.
-
(1999)
N Engl J Med
, vol.340
, pp. 901-907
-
-
Kearon, C.1
Gent, M.2
Hirsh, J.3
Weitz, J.4
Kovacs, M.J.5
Anderson, D.R.6
-
33
-
-
84856802635
-
Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
-
COI: 1:CAS:528:DC%2BC38XnsVOrtLY%3D, PID: 22315268
-
Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e419S–94S.
-
(2012)
Chest
, vol.141
, pp. e419S-e494S
-
-
Kearon, C.1
Akl, E.A.2
Comerota, A.J.3
Prandoni, P.4
Bounameaux, H.5
Goldhaber, S.Z.6
-
34
-
-
84886379226
-
Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: a systematic review
-
COI: 1:CAS:528:DC%2BC3sXht1OmsbvK, PID: 23760616
-
Garcia D, Akl EA, Carr R, Kearon C. Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: a systematic review. Blood. 2013;122:817–24.
-
(2013)
Blood
, vol.122
, pp. 817-824
-
-
Garcia, D.1
Akl, E.A.2
Carr, R.3
Kearon, C.4
-
35
-
-
0141791073
-
A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome
-
COI: 1:CAS:528:DC%2BD3sXnsV2jtb4%3D, PID: 13679527
-
Crowther MA, Ginsberg JS, Julian J, Denburg J, Hirsh J, Douketis J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 2003;349:1133–8.
-
(2003)
N Engl J Med
, vol.349
, pp. 1133-1138
-
-
Crowther, M.A.1
Ginsberg, J.S.2
Julian, J.3
Denburg, J.4
Hirsh, J.5
Douketis, J.6
-
36
-
-
23844437705
-
A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)
-
COI: 1:CAS:528:DC%2BD2MXltlOitL4%3D, PID: 15869575
-
Finazzi G, Marchioli R, Brancaccio V, Schinco P, Wisloff F, Musial J, et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost. 2005;3:848–53.
-
(2005)
J Thromb Haemost
, vol.3
, pp. 848-853
-
-
Finazzi, G.1
Marchioli, R.2
Brancaccio, V.3
Schinco, P.4
Wisloff, F.5
Musial, J.6
-
37
-
-
79953305113
-
Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies
-
COI: 1:STN:280:DC%2BC3M7nvVWqtw%3D%3D, PID: 21303837
-
Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I, Brey R, Crowther M, Derksen R, et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus. 2011;20:206–18.
-
(2011)
Lupus
, vol.20
, pp. 206-218
-
-
Ruiz-Irastorza, G.1
Cuadrado, M.J.2
Ruiz-Arruza, I.3
Brey, R.4
Crowther, M.5
Derksen, R.6
-
38
-
-
79961220976
-
Efficacy and safety of long-term low molecular weight heparin in patients with antiphospholipid syndrome
-
PID: 21628306
-
Vargas-Hitos JA, Ateka-Barrutia O, Sangle S, Khamashta MA. Efficacy and safety of long-term low molecular weight heparin in patients with antiphospholipid syndrome. Ann Rheum Dis. 2011;70:1652–4.
-
(2011)
Ann Rheum Dis
, vol.70
, pp. 1652-1654
-
-
Vargas-Hitos, J.A.1
Ateka-Barrutia, O.2
Sangle, S.3
Khamashta, M.A.4
-
40
-
-
84928625226
-
The use of rivaroxaban in patients with antiphospholipid syndrome: a series of 12 cases
-
COI: 1:CAS:528:DC%2BC2MXitl2ksrg%3D, PID: 25669601
-
Son M, Wypasek E, Celinska-Lowenhoff M, Undas A. The use of rivaroxaban in patients with antiphospholipid syndrome: a series of 12 cases. Thromb Res. 2015;135:1035–6.
-
(2015)
Thromb Res
, vol.135
, pp. 1035-1036
-
-
Son, M.1
Wypasek, E.2
Celinska-Lowenhoff, M.3
Undas, A.4
-
41
-
-
84908550562
-
Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients
-
PID: 25118790
-
Schaefer JK, McBane RD, Black DF, Williams LN, Moder KG, Wysokinski WE. Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients. Thromb Haemost. 2014;112:947–50.
-
(2014)
Thromb Haemost
, vol.112
, pp. 947-950
-
-
Schaefer, J.K.1
McBane, R.D.2
Black, D.F.3
Williams, L.N.4
Moder, K.G.5
Wysokinski, W.E.6
-
42
-
-
84907994966
-
New oral anticoagulants may not be effective to prevent venous thromboembolism in patients with antiphospholipid syndrome
-
COI: 1:CAS:528:DC%2BC2cXhsFyjtb%2FP, PID: 25043836
-
Win K, Rodgers GM. New oral anticoagulants may not be effective to prevent venous thromboembolism in patients with antiphospholipid syndrome. Am J Hematol. 2014;89:1017.
-
(2014)
Am J Hematol
, vol.89
, pp. 1017
-
-
Win, K.1
Rodgers, G.M.2
-
43
-
-
84930759043
-
Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome
-
COI: 1:CAS:528:DC%2BC2MXmsVersL4%3D, PID: 25864630
-
Noel N, Dutasta F, Costedoat-Chalumeau N, Bienvenu B, Mariette X, Geffray L, et al. Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome. Autoimmun Rev. 2015;14:680–5.
-
(2015)
Autoimmun Rev
, vol.14
, pp. 680-685
-
-
Noel, N.1
Dutasta, F.2
Costedoat-Chalumeau, N.3
Bienvenu, B.4
Mariette, X.5
Geffray, L.6
-
44
-
-
84938784417
-
Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE
-
COI: 1:CAS:528:DC%2BC2MXhvFWgu7nL, PID: 25940537
-
Cohen H, Doré CJ, Clawson S, Hunt BJ, Isenberg D, Khamashta M, et al. Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE. Lupus. 2015;24:1087–94.
-
(2015)
Lupus
, vol.24
, pp. 1087-1094
-
-
Cohen, H.1
Doré, C.J.2
Clawson, S.3
Hunt, B.J.4
Isenberg, D.5
Khamashta, M.6
-
45
-
-
84962752497
-
-
Rivaroxaban for antiphospholipid syndrome—clinicaltrials.gov [Internet]. clinicaltrials.gov. [cited 2016 Feb 13]. Available from:
-
Rivaroxaban for antiphospholipid syndrome—clinicaltrials.gov [Internet]. clinicaltrials.gov. [cited 2016 Feb 13]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02116036?term=rivaroxaban+antiphospholipid&rank=1
-
-
-
-
46
-
-
84962641980
-
-
Rivaroxaban in thrombotic antiphospholipid syndrome (TRAPS)—clinicaltrials.gov [Internet]. clinicaltrials.gov. [cited 2016 Feb 13]. Available from:
-
Rivaroxaban in thrombotic antiphospholipid syndrome (TRAPS)—clinicaltrials.gov [Internet]. clinicaltrials.gov. [cited 2016 Feb 13]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02157272?term=rivaroxaban+antiphospholipid&rank=2
-
-
-
-
47
-
-
10744223871
-
Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke
-
COI: 1:CAS:528:DC%2BD2cXhtVylurc%3D, PID: 14762036
-
Levine SR, Brey RL, Tilley BC, Thompson JLP, Sacco RL, Sciacca RR, et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA. 2004;291:576–84.
-
(2004)
JAMA
, vol.291
, pp. 576-584
-
-
Levine, S.R.1
Brey, R.L.2
Tilley, B.C.3
Thompson, J.L.P.4
Sacco, R.L.5
Sciacca, R.R.6
-
48
-
-
76149086177
-
Comparison between single antiplatelet therapy and combination of antiplatelet and anticoagulation therapy for secondary prevention in ischemic stroke patients with antiphospholipid syndrome
-
PID: 20046230
-
Okuma H, Kitagawa Y, Yasuda T, Tokuoka K, Takagi S. Comparison between single antiplatelet therapy and combination of antiplatelet and anticoagulation therapy for secondary prevention in ischemic stroke patients with antiphospholipid syndrome. Int J Med Sci. 2009;7:15–8.
-
(2009)
Int J Med Sci
, vol.7
, pp. 15-18
-
-
Okuma, H.1
Kitagawa, Y.2
Yasuda, T.3
Tokuoka, K.4
Takagi, S.5
-
49
-
-
37349061734
-
A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies
-
PID: 18050167
-
Ruiz-Irastorza G, Hunt BJ, Khamashta MA. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum. 2007;57:1487–95.
-
(2007)
Arthritis Rheum
, vol.57
, pp. 1487-1495
-
-
Ruiz-Irastorza, G.1
Hunt, B.J.2
Khamashta, M.A.3
-
50
-
-
0016184730
-
Prevention of postoperative deep venous thrombosis in legs by orally administered hydroxychloroquine sulphate
-
COI: 1:STN:280:DyaE2czgsF2itQ%3D%3D, PID: 4853767
-
Carter AE, Eban R. Prevention of postoperative deep venous thrombosis in legs by orally administered hydroxychloroquine sulphate. Br Med J. 1974;3:94–5.
-
(1974)
Br Med J
, vol.3
, pp. 94-95
-
-
Carter, A.E.1
Eban, R.2
-
51
-
-
0017651055
-
Prophylaxis of deep venous thrombosis by hydroxychloroquine sulfate and heparin
-
COI: 1:STN:280:DyaE1c%2FhsVaksw%3D%3D, PID: 333643
-
Wu TK, Tsapogas MJ, Jordan FR. Prophylaxis of deep venous thrombosis by hydroxychloroquine sulfate and heparin. Surg Gynecol Obstet. 1977;145:714–8.
-
(1977)
Surg Gynecol Obstet
, vol.145
, pp. 714-718
-
-
Wu, T.K.1
Tsapogas, M.J.2
Jordan, F.R.3
-
53
-
-
0017646633
-
Failure of orally administered hydroxychloroquine sulphate to prevent venous thromboembolism following elective hip operations
-
COI: 1:STN:280:DyaE2s7osl2rsw%3D%3D, PID: 325009
-
Cooke ED, Dawson MH, Ibbotson RM, Bowcock SA, Ainsworth ME, Pilcher MF. Failure of orally administered hydroxychloroquine sulphate to prevent venous thromboembolism following elective hip operations. J Bone Joint Surg Am. 1977;59:496–500.
-
(1977)
J Bone Joint Surg Am
, vol.59
, pp. 496-500
-
-
Cooke, E.D.1
Dawson, M.H.2
Ibbotson, R.M.3
Bowcock, S.A.4
Ainsworth, M.E.5
Pilcher, M.F.6
-
54
-
-
0023781805
-
Hydroxychloroquine and postoperative thromboembolism after total hip replacement
-
COI: 1:STN:280:DyaL1M%2Fitlaitg%3D%3D, PID: 3052057
-
Loudon JR. Hydroxychloroquine and postoperative thromboembolism after total hip replacement. Am J Med. 1988;85:57–61.
-
(1988)
Am J Med
, vol.85
, pp. 57-61
-
-
Loudon, J.R.1
-
55
-
-
0036045796
-
A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome
-
COI: 1:STN:280:DC%2BD38vgsVyqtw%3D%3D
-
Erkan D, Yazici Y, Peterson MG, Sammaritano L, Lockshin MD. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology (Oxford). 2002;41:924–9.
-
(2002)
Rheumatology (Oxford)
, vol.41
, pp. 924-929
-
-
Erkan, D.1
Yazici, Y.2
Peterson, M.G.3
Sammaritano, L.4
Lockshin, M.D.5
-
56
-
-
84885341807
-
Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients
-
COI: 1:CAS:528:DC%2BC3sXhs1Wnt73P, PID: 23902281
-
Schmidt-Tanguy A, Voswinkel J, Henrion D, Subra JF, Loufrani L, Rohmer V, et al. Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients. J Thromb Haemost. 2013;11:1927–9.
-
(2013)
J Thromb Haemost
, vol.11
, pp. 1927-1929
-
-
Schmidt-Tanguy, A.1
Voswinkel, J.2
Henrion, D.3
Subra, J.F.4
Loufrani, L.5
Rohmer, V.6
-
57
-
-
84921026907
-
Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies
-
COI: 1:CAS:528:DC%2BC2cXhvVamsLrO, PID: 25461472, A meta-analysis that points to a protective effect of aspirin both for SLE patients with antiphospholipid antibodies and asymptomatic carriers of antiphospholipid antibodies
-
Arnaud L, Mathian A, Devilliers H, Ruffatti A, Tektonidou M, Forastiero R, et al. Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. Autoimmun Rev. 2015;14:192–200. A meta-analysis that points to a protective effect of aspirin both for SLE patients with antiphospholipid antibodies and asymptomatic carriers of antiphospholipid antibodies.
-
(2015)
Autoimmun Rev
, vol.14
, pp. 192-200
-
-
Arnaud, L.1
Mathian, A.2
Devilliers, H.3
Ruffatti, A.4
Tektonidou, M.5
Forastiero, R.6
-
58
-
-
0027457735
-
Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus
-
COI: 1:STN:280:DyaK3s3htFajsA%3D%3D, PID: 8096266
-
Vaarala O, Alfthan G, Jauhiainen M, Leirisalo-Repo M, Aho K, Palosuo T. Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet. 1993;341:923–5.
-
(1993)
Lancet
, vol.341
, pp. 923-925
-
-
Vaarala, O.1
Alfthan, G.2
Jauhiainen, M.3
Leirisalo-Repo, M.4
Aho, K.5
Palosuo, T.6
-
59
-
-
0032530883
-
Induction of early atherosclerosis in LDL-receptor-deficient mice immunized with beta2-glycoprotein I
-
COI: 1:CAS:528:DyaK1cXmt1Wjtrc%3D, PID: 9736598
-
George J, Afek A, Gilburd B, Blank M, Levy Y, Aron-Maor A, et al. Induction of early atherosclerosis in LDL-receptor-deficient mice immunized with beta2-glycoprotein I. Circulation. 1998;98:1108–15.
-
(1998)
Circulation
, vol.98
, pp. 1108-1115
-
-
George, J.1
Afek, A.2
Gilburd, B.3
Blank, M.4
Levy, Y.5
Aron-Maor, A.6
-
60
-
-
0032587108
-
Immunolocalization of beta2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression
-
COI: 1:CAS:528:DyaK1MXjtFKku7s%3D, PID: 10226085
-
George J, Harats D, Gilburd B, Afek A, Levy Y, Schneiderman J, et al. Immunolocalization of beta2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression. Circulation. 1999;99:2227–30.
-
(1999)
Circulation
, vol.99
, pp. 2227-2230
-
-
George, J.1
Harats, D.2
Gilburd, B.3
Afek, A.4
Levy, Y.5
Schneiderman, J.6
-
61
-
-
3042797102
-
Endothelial cell activation by antiphospholipid antibodies
-
COI: 1:CAS:528:DC%2BD2cXls1eit7w%3D, PID: 15240160
-
Meroni PL, Raschi E, Testoni C, Borghi MO. Endothelial cell activation by antiphospholipid antibodies. Clin Immunol. 2004;112:169–74.
-
(2004)
Clin Immunol
, vol.112
, pp. 169-174
-
-
Meroni, P.L.1
Raschi, E.2
Testoni, C.3
Borghi, M.O.4
-
62
-
-
7244237671
-
Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells
-
COI: 1:CAS:528:DC%2BD2cXosF2rtLg%3D, PID: 15333031
-
Ferrara DE, Swerlick R, Casper K, Meroni PL, Vega-Ostertag ME, Harris EN, et al. Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells. J Thromb Haemost. 2004;2:1558–63.
-
(2004)
J Thromb Haemost
, vol.2
, pp. 1558-1563
-
-
Ferrara, D.E.1
Swerlick, R.2
Casper, K.3
Meroni, P.L.4
Vega-Ostertag, M.E.5
Harris, E.N.6
-
63
-
-
56749106312
-
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein
-
COI: 1:CAS:528:DC%2BD1cXhtl2gurnL, PID: 18997196
-
Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–207.
-
(2008)
N Engl J Med
, vol.359
, pp. 2195-2207
-
-
Ridker, P.M.1
Danielson, E.2
Fonseca, F.A.H.3
Genest, J.4
Gotto, A.M.5
Kastelein, J.J.P.6
-
64
-
-
84899916939
-
A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients
-
COI: 1:CAS:528:DC%2BC2cXhtV2isLrE, PID: 23933625
-
Erkan D, Willis R, Murthy VL, Basra G, Vega J, Ruiz-Limón P, et al. A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients. Ann Rheum Dis. 2014;73:1176–80.
-
(2014)
Ann Rheum Dis
, vol.73
, pp. 1176-1180
-
-
Erkan, D.1
Willis, R.2
Murthy, V.L.3
Basra, G.4
Vega, J.5
Ruiz-Limón, P.6
-
65
-
-
65449138698
-
A randomized trial of rosuvastatin in the prevention of venous thromboembolism
-
COI: 1:CAS:528:DC%2BD1MXlsVSlurk%3D, PID: 19329822
-
Glynn RJ, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med. 2009;360:1851–61.
-
(2009)
N Engl J Med
, vol.360
, pp. 1851-1861
-
-
Glynn, R.J.1
Danielson, E.2
Fonseca, F.A.H.3
Genest, J.4
Gotto, A.M.5
Kastelein, J.J.P.6
-
66
-
-
80055098706
-
Statins in the prevention of venous thromboembolism: a meta-analysis of observational studies
-
COI: 1:CAS:528:DC%2BC3MXhtl2ntrvE, PID: 21641019
-
Pai M, Evans NS, Shah SJ, Green D, Cook D, Crowther MA. Statins in the prevention of venous thromboembolism: a meta-analysis of observational studies. Thromb Res. 2011;128:422–30.
-
(2011)
Thromb Res
, vol.128
, pp. 422-430
-
-
Pai, M.1
Evans, N.S.2
Shah, S.J.3
Green, D.4
Cook, D.5
Crowther, M.A.6
-
67
-
-
84873846125
-
A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome
-
COI: 1:CAS:528:DC%2BC3sXhsFCjurY%3D, PID: 23124321, The first clinical trial of Rituximab in APS
-
Erkan D, Vega J, Ramón G, Kozora E, Lockshin MD. A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome. Arthritis Rheum. 2013;65:464–71. The first clinical trial of Rituximab in APS.
-
(2013)
Arthritis Rheum
, vol.65
, pp. 464-471
-
-
Erkan, D.1
Vega, J.2
Ramón, G.3
Kozora, E.4
Lockshin, M.D.5
-
68
-
-
13244275118
-
Long-term remission from life-threatening hypercoagulable state associated with lupus anticoagulant (LA) following rituximab therapy
-
PID: 15682409
-
Ahn ER, Lander G, Bidot CJ, Jy W, Ahn YS. Long-term remission from life-threatening hypercoagulable state associated with lupus anticoagulant (LA) following rituximab therapy. Am J Hematol. 2005;78:127–9.
-
(2005)
Am J Hematol
, vol.78
, pp. 127-129
-
-
Ahn, E.R.1
Lander, G.2
Bidot, C.J.3
Jy, W.4
Ahn, Y.S.5
-
69
-
-
38049059906
-
Rituximab effectively reverses papilledema associated with cerebral venous sinus thrombosis in antiphospholipid antibody syndrome
-
COI: 1:STN:280:DC%2BD2sngvVGntw%3D%3D, PID: 17932872
-
Chalam KV, Gupta SK, Agarwal S. Rituximab effectively reverses papilledema associated with cerebral venous sinus thrombosis in antiphospholipid antibody syndrome. Eur J Ophthalmol. 2007;17:867–70.
-
(2007)
Eur J Ophthalmol
, vol.17
, pp. 867-870
-
-
Chalam, K.V.1
Gupta, S.K.2
Agarwal, S.3
-
70
-
-
84857190406
-
Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation
-
COI: 1:CAS:528:DC%2BC3MXhsFCmtLvM, PID: 21831149
-
Hadaya K, Ferrari-Lacraz S, Fumeaux D, Boehlen F, Toso C, Moll S, et al. Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation. Am J Transplant. 2011;11:2523–7.
-
(2011)
Am J Transplant
, vol.11
, pp. 2523-2527
-
-
Hadaya, K.1
Ferrari-Lacraz, S.2
Fumeaux, D.3
Boehlen, F.4
Toso, C.5
Moll, S.6
-
71
-
-
84895064562
-
Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation
-
COI: 1:CAS:528:DC%2BC2cXhs1eqsbc%3D, PID: 24400968
-
Lonze BE, Zachary AA, Magro CM, Desai NM, Orandi BJ, Dagher NN, et al. Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation. Am J Transplant. 2014;14:459–65.
-
(2014)
Am J Transplant
, vol.14
, pp. 459-465
-
-
Lonze, B.E.1
Zachary, A.A.2
Magro, C.M.3
Desai, N.M.4
Orandi, B.J.5
Dagher, N.N.6
-
72
-
-
84962759140
-
-
Eculizumab for CAPS patients undergoing renal transplantation—clinicaltrials.gov [Internet]. clinicaltrials.gov. [cited 2016 Feb 14]. Available from
-
Eculizumab for CAPS patients undergoing renal transplantation—clinicaltrials.gov [Internet]. clinicaltrials.gov. [cited 2016 Feb 14]. Available from: https://clinicaltrials.gov/ct2/show/NCT01029587?term=catastrophic+antiphospholipid&rank=1
-
-
-
-
73
-
-
84861541673
-
Vitamin D and antiphospholipid syndrome
-
COI: 1:CAS:528:DC%2BC38XhtFWhtb%2FK, PID: 22635218
-
Andreoli L, Piantoni S, Dall'Ara F, Allegri F, Meroni PL, Tincani A. Vitamin D and antiphospholipid syndrome. Lupus. 2012;21:736–40.
-
(2012)
Lupus
, vol.21
, pp. 736-740
-
-
Andreoli, L.1
Piantoni, S.2
Dall'Ara, F.3
Allegri, F.4
Meroni, P.L.5
Tincani, A.6
-
74
-
-
78650676621
-
Vitamin D: an instrumental factor in the anti-phospholipid syndrome by inhibition of tissue factor expression
-
COI: 1:CAS:528:DC%2BC3MXhtleit7g%3D, PID: 20980705
-
Agmon-Levin N, Blank M, Zandman-Goddard G, Orbach H, Meroni PL, Tincani A, et al. Vitamin D: an instrumental factor in the anti-phospholipid syndrome by inhibition of tissue factor expression. Ann Rheum Dis. 2011;70:145–50.
-
(2011)
Ann Rheum Dis
, vol.70
, pp. 145-150
-
-
Agmon-Levin, N.1
Blank, M.2
Zandman-Goddard, G.3
Orbach, H.4
Meroni, P.L.5
Tincani, A.6
-
75
-
-
0029953246
-
Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry
-
COI: 1:STN:280:DyaK283ktVWgtg%3D%3D, PID: 8644765
-
Finazzi G, Brancaccio V, Moia M, Ciaverella N, Mazzucconi MG, Schinco PC, et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med. 1996;100:530–6.
-
(1996)
Am J Med
, vol.100
, pp. 530-536
-
-
Finazzi, G.1
Brancaccio, V.2
Moia, M.3
Ciaverella, N.4
Mazzucconi, M.G.5
Schinco, P.C.6
-
76
-
-
34547407889
-
Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals
-
COI: 1:CAS:528:DC%2BD2sXovFSgurs%3D, PID: 17599766
-
Erkan D, Harrison MJ, Levy R, Peterson M, Petri M, Sammaritano L, et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum. 2007;56:2382–91.
-
(2007)
Arthritis Rheum
, vol.56
, pp. 2382-2391
-
-
Erkan, D.1
Harrison, M.J.2
Levy, R.3
Peterson, M.4
Petri, M.5
Sammaritano, L.6
-
77
-
-
84892535614
-
Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS)
-
COI: 1:CAS:528:DC%2BC2cXhtVOht7c%3D
-
Cuadrado MJ, Bertolaccini ML, Seed PT, Tektonidou MG, Aguirre A, Mico L, et al. Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS). Rheumatology (Oxford). 2014;53:275–84.
-
(2014)
Rheumatology (Oxford)
, vol.53
, pp. 275-284
-
-
Cuadrado, M.J.1
Bertolaccini, M.L.2
Seed, P.T.3
Tektonidou, M.G.4
Aguirre, A.5
Mico, L.6
-
78
-
-
84878655408
-
The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus
-
COI: 1:CAS:528:DC%2BC3sXhtV2mtbnN, PID: 23588942
-
Akhavan PS, Su J, Lou W, Gladman DD, Urowitz MB, Fortin PR. The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus. J Rheumatol. 2013;40:831–41.
-
(2013)
J Rheumatol
, vol.40
, pp. 831-841
-
-
Akhavan, P.S.1
Su, J.2
Lou, W.3
Gladman, D.D.4
Urowitz, M.B.5
Fortin, P.R.6
-
79
-
-
0026074414
-
A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus
-
79. Bykerk V, Sampalis J, Esdaile JM, choquette D, Senecal JL, Danoff D, et al. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N. Engl. J. Med. 1991;324:150–4.
-
(1991)
N. Engl. J. Med
, vol.324
, pp. 150-154
-
-
Bykerk, V.1
Sampalis, J.2
Esdaile, J.M.3
choquette, D.4
Senecal, J.L.5
Danoff, D.6
-
80
-
-
84867498972
-
Hydroxychloroquine reduces low-density lipoprotein cholesterol levels in systemic lupus erythematosus: a longitudinal evaluation of the lipid-lowering effect
-
COI: 1:CAS:528:DC%2BC2cXhslWju7nP, PID: 22641182
-
Cairoli E, Rebella M, Danese N, Garra V, Borba EF. Hydroxychloroquine reduces low-density lipoprotein cholesterol levels in systemic lupus erythematosus: a longitudinal evaluation of the lipid-lowering effect. Lupus. 2012;21:1178–82.
-
(2012)
Lupus
, vol.21
, pp. 1178-1182
-
-
Cairoli, E.1
Rebella, M.2
Danese, N.3
Garra, V.4
Borba, E.F.5
-
81
-
-
67049088535
-
Treatment of lupus skin involvement with quinacrine and hydroxychloroquine
-
COI: 1:CAS:528:DC%2BD1MXptVOjtbg%3D, PID: 19502270
-
Cavazzana I, Sala R, Bazzani C, Ceribelli A, Zane C, Cattaneo R, et al. Treatment of lupus skin involvement with quinacrine and hydroxychloroquine. Lupus. 2009;18:735–9.
-
(2009)
Lupus
, vol.18
, pp. 735-739
-
-
Cavazzana, I.1
Sala, R.2
Bazzani, C.3
Ceribelli, A.4
Zane, C.5
Cattaneo, R.6
-
82
-
-
73449120372
-
Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review
-
COI: 1:CAS:528:DC%2BC3cXhtFOlsrk%3D, PID: 19103632
-
Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis. 2010;69:20–8.
-
(2010)
Ann Rheum Dis
, vol.69
, pp. 20-28
-
-
Ruiz-Irastorza, G.1
Ramos-Casals, M.2
Brito-Zeron, P.3
Khamashta, M.A.4
-
83
-
-
33750499270
-
Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus
-
COI: 1:CAS:528:DC%2BD28Xht1Gru7zJ, PID: 17080912
-
Ruiz-Irastorza G, Egurbide MV, Pijoan JI, Garmendia M, Villar I, Martinez-Berriotxoa A, et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus. 2006;15:577–83.
-
(2006)
Lupus
, vol.15
, pp. 577-583
-
-
Ruiz-Irastorza, G.1
Egurbide, M.V.2
Pijoan, J.I.3
Garmendia, M.4
Villar, I.5
Martinez-Berriotxoa, A.6
-
84
-
-
58349097555
-
Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies
-
PID: 19116963
-
Tektonidou MG, Laskari K, Panagiotakos DB, Moutsopoulos HM. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum. 2009;61:29–36.
-
(2009)
Arthritis Rheum
, vol.61
, pp. 29-36
-
-
Tektonidou, M.G.1
Laskari, K.2
Panagiotakos, D.B.3
Moutsopoulos, H.M.4
-
85
-
-
65149094443
-
Prevalence, predictors and outcome of vascular damage in systemic lupus erythematosus
-
COI: 1:STN:280:DC%2BD1Mzgtlamsw%3D%3D, PID: 19395452
-
Becker-Merok A, Nossent J. Prevalence, predictors and outcome of vascular damage in systemic lupus erythematosus. Lupus. 2009;18:508–15.
-
(2009)
Lupus
, vol.18
, pp. 508-515
-
-
Becker-Merok, A.1
Nossent, J.2
-
86
-
-
84871867984
-
Hydroxychloroquine use is associated with lower odds of persistently positive antiphospholipid antibodies and/or lupus anticoagulant in systemic lupus erythematosus
-
COI: 1:CAS:528:DC%2BC3sXhvV2huro%3D, PID: 22859353
-
Broder A, Putterman C. Hydroxychloroquine use is associated with lower odds of persistently positive antiphospholipid antibodies and/or lupus anticoagulant in systemic lupus erythematosus. J Rheumatol. 2013;40:30–3.
-
(2013)
J Rheumatol
, vol.40
, pp. 30-33
-
-
Broder, A.1
Putterman, C.2
-
87
-
-
84861551121
-
CAPS Registry
-
COI: 1:STN:280:DC%2BC38nms1Wqtw%3D%3D, PID: 22635223
-
Cervera R. CAPS Registry. Lupus. 2012;21:755–7.
-
(2012)
Lupus
, vol.21
, pp. 755-757
-
-
Cervera, R.1
|